Search

Your search keyword '"Quirce S"' showing total 1,136 results
Start Over Author "Quirce S"
1,136 results on '"Quirce S"'

1. Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy

Author

Quirce S, Heffler E, Nenasheva N, Demoly P, Menzies-Gow A, Moreira-Jorge A, Nissen F, and Hanania NA

Subjects
asthma, diagnosis, age of onset, allergy, allergic asthma, asthma phenotypes, Immunologic diseases. Allergy, RC581-607
Abstract

Santiago Quirce,1 Enrico Heffler,2 Natalia Nenasheva,3 Pascal Demoly,4 Andrew Menzies-Gow,5 Ana Moreira-Jorge,6 Francis Nissen,7 Nicola A Hanania8 1Department of Allergy, La Paz University Hospital, IdiPAZ and Universidad Autónoma de Madrid, Madrid, Spain; 2Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center, IRCCS, Rozzano, MI, Italy; 3Department of Allergology and Immunology of Russian Medical Academy for Continuous Medical Education, Moscow, Russian Federation; 4Department of Pulmonology, Division of Allergy, Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, Montpellier, France; 5Department of Respiratory Medicine, Royal Brompton Hospital, London, UK; 6Novartis Farmaceutica, S.A., Barcelona, Spain; 7London School of Hygiene and Tropical Medicine, London, UK; 8Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USACorrespondence: Santiago QuirceHospital Universitario La Paz, P. La Castellana, 261, Madrid, 28046 SpainEmail squirce@gmail.comAbstract: The Global Initiative for Asthma (GINA) 2020 defines late-onset asthma (LOA) as one of the clinical phenotypes of asthma wherein patients, particularly women, present with asthma for the first time in adult life, tend to be non-allergic and often require higher doses of inhaled corticosteroids (ICS) or are relatively refractory to corticosteroid treatment. In this review, we examine the published literature improve the understanding of the following aspects of LOA: 1) the age cut-off for its diagnosis; 2) its distinct clinical phenotypes, characteristics and risk factors; and 3) its association with allergic comorbidities and conditions. Overall, our review reveals that clinicians and researchers have used multiple age cut-offs to define LOA, with cut-off ages ranging from > 12 years to ≥ 65 years. LOA has also been classified into several distinct phenotypes, some of which drastically differ in their clinical characteristics, course and prognosis. Although LOA has traditionally been considered non-allergic in nature, our review indicates that it is commonly associated with allergic features and comorbidities. Our findings suggest that there is an urgent need for the development of more clear clinical practice guidelines that can provide more clarity on the definition and other aspects of LOA. In addition, the association of LOA and allergy needs to be re-examined to frame a more optimal treatment strategy for patients with LOA.Keywords: asthma, diagnosis, age of onset, allergy, allergic asthma, asthma phenotypes

Published
2020

2. FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma

Author

Cabrejos S, Moreira A, Ramirez A, Quirce S, Soto Campos G, Dávila I, and Campo P

Subjects
asthma, omalizumab, allergy, exacerbations, ige, Immunologic diseases. Allergy, RC581-607
Abstract

Sheila Cabrejos,1 Ana Moreira,2 Andreina Ramirez,2 Santiago Quirce,3 Gregorio Soto Campos,4 Ignacio Dávila,5 Paloma Campo6 1Allergy Service, Hospital Rafael Mendez de Lorca, Murcia, Spain; 2Novartis Farmacéutica, Barcelona, Spain; 3Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain; 4Pneumology and Allergy Unit, Hospital Universitario de Jerez, Cádiz, Spain; 5Allergy Service, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain, Biomedical and Diagnosis Science Department, Salamanca University School of Medicine, Salamanca, Spain; 6Allergy Unit, IBIMA-Regional University Hospital of Málaga, ARADyAL, Málaga, SpainCorrespondence: Ignacio DávilaAllergy Service, University Hospital of Salamanca and Institute for Biomedical Research of Salamanca (IBSAL), Paseo de San Vicente, 58-182, Salamanca 37007, SpainTel +34923291100 (55373)Email idg@usal.esIntroduction: A Spanish real-world study in patients with severe persistent asthma who achieved asthma control after a one-year treatment with omalizumab highlighted the phenotypic heterogeneity of these patients (FENOMA study). In this subanalysis, we describe the clinical improvement in patients with severe allergic asthma in this study (positive skin test and IgE level 30– 1500 IU/mL); n=240.Patients and Methods: FENOMA was an observational, multicentre, retrospective study in 345 patients achieving asthma control according to Spanish guidelines (GEMA). Baseline demographic and asthma-related characteristics were collected. Outcomes analyzed were those included in asthma control definition plus changes in background treatments and in blood eosinophil count (%) and exhaled nitric oxide fraction [FeNO].Results: At baseline, patients were aged 45.4± 15.0 years; 67% were women. Median (Q1;Q3) IgE levels were 302.5 (154.0; 553.5) IU/mL. After one-year treatment with omalizumab: 43.3% of patients had daytime symptoms vs 97.7% before treatment and 49.6% stopped taking oral corticosteroids. FEV1 increased a median of 12.0 (4.0; 23.0)%; P < 0.0001. The number of non-severe asthma exacerbations decreased a median of − 4.0 (− 7.0; 2.0); P < 0.0001. Median unplanned visits to primary care or specialists and days of school/workplace absenteeism decreased from 4.9 (2.0; 6.0), 1.0 (0.0; 3.0) and 0.0 (0.0; 14.0) to 0.0 (0.0; 1.0), 0.0 (0.0; 0.0) and 0.0 (0.0; 0.0), respectively. Median eosinophil blood count and FeNO decreased from 5.0 (3:0; 8.0)% to 3.0 (2.0; 5.5)% and from 36.0 (23:0; 53.0) ppb to 20.0 (13.0; 34.0) ppb, respectively.Conclusion: This study highlights the asthma control achieved by patients with severe allergic asthma treated with omalizumab, with relevant benefits on the burden of the disease both on patients and the healthcare system.Keywords: asthma, omalizumab, allergy, exacerbations, IgE

Published
2020

3. Non-eosinophilic asthma: current perspectives

Author

Esteban-Gorgojo I, Antolín-Amérigo D, Domínguez-Ortega J, and Quirce S

Subjects
Asthma, non-eosinophilic asthma, asthma phenotype, asthma endotype, neutrophilic asthma, Immunologic diseases. Allergy, RC581-607
Abstract

Ignacio Esteban-Gorgojo,1 Darío Antolín-Amérigo,2 Javier Domínguez-Ortega,3,4 Santiago Quirce3,4 1Department of Allergy, Hospital General de Villalba, Madrid, Spain; 2Department of Allergy, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain; 3Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), 4CIBER de Enfermedades Respiratorias, CIBERES, Madrid, Spain Abstract: Although non-eosinophilic asthma (NEA) is not the best known and most prevalent asthma phenotype, its importance cannot be underestimated. NEA is characterized by airway inflammation with the absence of eosinophils, subsequent to activation of non-predominant type 2 immunologic pathways. This phenotype, which possibly includes several not well-defined subphenotypes, is defined by an eosinophil count

Published
2018

4. Dupilumab in the management of moderate-to-severe asthma: the data so far

Author

Barranco P, Phillips-Angles E, Dominguez-Ortega J, and Quirce S

Subjects
dupilumab, asthma, interleukin-4, interleukin-13, monoclonal antibodies, treatment, Therapeutics. Pharmacology, RM1-950
Abstract

Pilar Barranco,1 Elsa Phillips-Angles,2 Javier Dominguez-Ortega,1 Santiago Quirce1 1Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), CIBER de Enfermedades Respiratorias (CIBERES), Madrid, Spain; 2Department of Allergy, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain Abstract: Severe asthma constitutes illness in a relatively small proportion of all patients with asthma, but it is a major public health problem – with considerable effect on morbidity, mortality, as well as a high burden on health care resources. Regardless of effective treatments being widely available and the existence of treatment guidelines, a large population of severe asthma cases remain uncontrolled. Achieving and maintaining asthma control in this group of patients is, therefore, of utmost importance. The recognition of distinct inflammatory phenotypes within this population has driven the development of targeted biological therapies – particularly, selective targeted monoclonal antibodies (mAbs). It is noteworthy that in approximately 50% of these patients, there is strong evidence of the pathogenic role of T helper type-2 (Th2) cytokines, such as interleukin (IL)-4 and IL-13, orchestrating the eosinophilic and allergic inflammatory processes. Among the recently developed antiasthma biologic drugs, the mAb dupilumab is very promising given its ability to inhibit the biological effects of both IL-4 and IL-13. In this review, we focused on IL-4 and IL-13, as these interleukins are considered to play a key role in the pathophysiology of asthma, and on dupilumab, an anti-IL-4 receptor human mAb, as a forthcoming treatment for uncontrolled severe asthma in the near future. Keywords: dupilumab, asthma, interleukin-4, interleukin-13, monoclonal antibodies, treatment

Published
2017

6. Pre-asthma: a useful concept? A EUFOREA paper. Part 2—late onset eosinophilic asthma

Author

Scadding, G. K., primary, Gray, C., additional, Conti, D. M., additional, McDonald, M., additional, Backer, V., additional, Scadding, G., additional, Bernal-Sprekelsen, M., additional, De Corso, E., additional, Diamant, Z., additional, Hopkins, C., additional, Jesenak, M., additional, Johansen, P., additional, Kappen, J., additional, Mullol, J., additional, Price, D., additional, Quirce, S., additional, Reitsma, S., additional, Toppila-Salmi, S., additional, Senior, B., additional, Thyssen, J. P., additional, Wahn, U., additional, and Hellings, P. W., additional

Published
2024
Full Text
View/download PDF

8. Pre-asthma: a useful concept for prevention and disease-modification? A EUFOREA paper. Part 1—allergic asthma

Author

Scadding, G. K., primary, McDonald, M., additional, Backer, V., additional, Scadding, G., additional, Bernal-Sprekelsen, M., additional, Conti, D. M., additional, De Corso, E., additional, Diamant, Z., additional, Gray, C., additional, Hopkins, C., additional, Jesenak, M., additional, Johansen, P., additional, Kappen, J., additional, Mullol, J., additional, Price, D., additional, Quirce, S., additional, Reitsma, S., additional, Salmi, S., additional, Senior, B., additional, Thyssen, J. P., additional, Wahn, U., additional, and Hellings, P. W., additional

Published
2024
Full Text
View/download PDF

15. Exacerbations Among Patients With Asthma Are Largely Dependent on the Presence of Multimorbidity

Author

Domínguez-Ortega, J, primary, Luna-Porta, JA, additional, Olaguibel, JM, additional, Barranco, P, additional, Arismendi, E, additional, Barroso, B, additional, Betancor, D, additional, Bobolea, I, additional, Caballero, ML, additional, Cárdaba, B, additional, Cruz, MJ, additional, Curto, E, additional, González-Barcala, FJ, additional, Losantos-García, I, additional, Martínez-Rivera, C, additional, Mendez-Brea, P, additional, Mullol, J, additional, Muñoz, X, additional, Picado, C, additional, Plaza, V, additional, del Pozo, V, additional, Rial, MJ, additional, Sastre, J, additional, Soto, L, additional, Valero, A, additional, Valverde-Monge, M, additional, and Quirce, S, additional

Published
2023
Full Text
View/download PDF

16. Lung Function Abnormalities and Their Correlation With Clinical Characteristics and Inflammatory Markers in Adult Asthma

Author

Betancor, C, primary, Olaguibel, JM, additional, Rodrigo-Muñoz, JM, additional, Alvarez Puebla, MJ, additional, Arismendi, E, additional, Barranco, P, additional, Barroso, B, additional, Bobolea, I, additional, Cárdaba, B, additional, Cruz, MJ, additional, Curto, E, additional, Del Pozo, V, additional, Domínguez-Ortega, J, additional, González-Barcala, FJ, additional, Luna-Porta, JA, additional, Martínez-Rivera, C, additional, Mullol, J, additional, Muñoz, X, additional, Picado, C, additional, Plaza, V, additional, Quirce, S, additional, Rial, MJ, additional, Soto-Retes, L, additional, Valero, A, additional, Valverde-Monge, M, additional, and Sastre, J, additional

Published
2023
Full Text
View/download PDF

19. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis

Author

Bousquet, J., primary, Melén, E., additional, Haahtela, T., additional, Koppelman, G. H., additional, Togias, A., additional, Valenta, R., additional, Akdis, C. A., additional, Czarlewski, W., additional, Rothenberg, M., additional, Valiulis, A., additional, Wickman, M., additional, Akdis, M., additional, Aguilar, D., additional, Bedbrook, A., additional, Bindslev‐Jensen, C., additional, Bosnic‐Anticevich, S., additional, Boulet, L. P., additional, Brightling, C. E., additional, Brussino, L., additional, Burte, E., additional, Bustamante, M., additional, Canonica, G. W., additional, Cecchi, L., additional, Celedon, J. C., additional, Chaves Loureiro, C., additional, Costa, E., additional, Cruz, A. A., additional, Erhola, M., additional, Gemicioglu, B., additional, Fokkens, W. J., additional, Garcia‐Aymerich, J., additional, Guerra, S., additional, Heinrich, J., additional, Ivancevich, J. C., additional, Keil, T., additional, Klimek, L., additional, Kuna, P., additional, Kupczyk, M., additional, Kvedariene, V., additional, Larenas‐Linnemann, D. E., additional, Lemonnier, N., additional, Lodrup Carlsen, K. C., additional, Louis, R., additional, Makela, M., additional, Makris, M., additional, Maurer, M., additional, Momas, I., additional, Morais‐Almeida, M., additional, Mullol, J., additional, Naclerio, R. N., additional, Nadeau, K., additional, Nadif, R., additional, Niedoszytko, M., additional, Okamoto, Y., additional, Ollert, M., additional, Papadopoulos, N. G., additional, Passalacqua, G., additional, Patella, V., additional, Pawankar, R., additional, Pham‐Thi, N., additional, Pfaar, O., additional, Regateiro, F. S., additional, Ring, J., additional, Rouadi, P. W., additional, Samolinski, B., additional, Sastre, J., additional, Savouré, M., additional, Scichilone, N., additional, Shamji, M. H., additional, Sheikh, A., additional, Siroux, V., additional, Sousa‐Pinto, B., additional, Standl, M., additional, Sunyer, J., additional, Taborda‐Barata, L., additional, Toppila‐Salmi, S., additional, Torres, M. J., additional, Tsiligianni, I., additional, Valovirta, E., additional, Vandenplas, O., additional, Ventura, M. T., additional, Weiss, S., additional, Yorgancioglu, A., additional, Zhang, L., additional, Abdul Latiff, A. H., additional, Aberer, W., additional, Agache, I., additional, Al‐Ahmad, M., additional, Alobid, I., additional, Ansotegui, I. J., additional, Arshad, S. H., additional, Asayag, E., additional, Barbara, C., additional, Baharudin, A., additional, Battur, L., additional, Bennoor, K. S., additional, Berghea, E. C., additional, Bergmann, K. C., additional, Bernstein, D., additional, Bewick, M., additional, Blain, H., additional, Bonini, M., additional, Braido, F., additional, Buhl, R., additional, Bumbacea, R. S., additional, Bush, A., additional, Calderon, M., additional, Calvo‐Gil, M., additional, Camargos, P., additional, Caraballo, L., additional, Cardona, V., additional, Carr, W., additional, Carreiro‐Martins, P., additional, Casale, T., additional, Cepeda Sarabia, A. M., additional, Chandrasekharan, R., additional, Charpin, D., additional, Chen, Y. Z., additional, Cherrez‐Ojeda, I., additional, Chivato, T., additional, Chkhartishvili, E., additional, Christoff, G., additional, Chu, D. K., additional, Cingi, C., additional, Correia de Sousa, J., additional, Corrigan, C., additional, Custovic, A., additional, D’Amato, G., additional, Del Giacco, S., additional, De Blay, F., additional, Devillier, P., additional, Didier, A., additional, do Ceu Teixeira, M., additional, Dokic, D., additional, Douagui, H., additional, Doulaptsi, M., additional, Durham, S., additional, Dykewicz, M., additional, Eiwegger, T., additional, El‐Sayed, Z. A., additional, Emuzyte, R., additional, Fiocchi, A., additional, Fyhrquist, N., additional, Gomez, R. M., additional, Gotua, M., additional, Guzman, M. A., additional, Hagemann, J., additional, Hamamah, S., additional, Halken, S., additional, Halpin, D. M. G., additional, Hofmann, M., additional, Hossny, E., additional, Hrubiško, M., additional, Irani, C., additional, Ispayeva, Z., additional, Jares, E., additional, Jartti, T., additional, Jassem, E., additional, Julge, K., additional, Just, J., additional, Jutel, M., additional, Kaidashev, I., additional, Kalayci, O., additional, Kalyoncu, A. F., additional, Kardas, P., additional, Kirenga, B., additional, Kraxner, H., additional, Kull, I., additional, Kulus, M., additional, La Grutta, S., additional, Lau, S., additional, Le Tuyet Thi, L., additional, Levin, M., additional, Lipworth, B., additional, Lourenço, O., additional, Mahboub, B., additional, Martinez‐Infante, E., additional, Matricardi, P., additional, Miculinic, N., additional, Migueres, N., additional, Mihaltan, F., additional, Mohammad, Y., additional, Moniuszko, M., additional, Montefort, S., additional, Neffen, H., additional, Nekam, K., additional, Nunes, E., additional, Nyembue Tshipukane, D., additional, O’Hehir, R., additional, Ogulur, I., additional, Ohta, K., additional, Okubo, K., additional, Ouedraogo, S., additional, Olze, H., additional, Pali‐Schöll, I., additional, Palomares, O., additional, Palosuo, K., additional, Panaitescu, C., additional, Panzner, P., additional, Park, H. S., additional, Pitsios, C., additional, Plavec, D., additional, Popov, T. A., additional, Puggioni, F., additional, Quirce, S., additional, Recto, M., additional, Repka‐Ramirez, M. S., additional, Robalo Cordeiro, C., additional, Roche, N., additional, Rodriguez‐Gonzalez, M., additional, Romantowski, J., additional, Rosario Filho, N., additional, Rottem, M., additional, Sagara, H., additional, Serpa, F. S., additional, Sayah, Z., additional, Scheire, S., additional, Schmid‐Grendelmeier, P., additional, Sisul, J. C., additional, Sole, D., additional, Soto‐Martinez, M., additional, Sova, M., additional, Sperl, A., additional, Spranger, O., additional, Stelmach, R., additional, Suppli Ulrik, C., additional, Thomas, M., additional, To, T., additional, Todo‐Bom, A., additional, Tomazic, P. V., additional, Urrutia‐Pereira, M., additional, Valentin‐Rostan, M., additional, Van Ganse, E., additional, van Hage, M., additional, Vasankari, T., additional, Vichyanond, P., additional, Viegi, G., additional, Wallace, D., additional, Wang, D. Y., additional, Williams, S., additional, Worm, M., additional, Yiallouros, P., additional, Yusuf, O., additional, Zaitoun, F., additional, Zernotti, M., additional, Zidarn, M., additional, Zuberbier, J., additional, Fonseca, J. A., additional, Zuberbier, T., additional, and Anto, J. M., additional

Published
2023
Full Text
View/download PDF

25. The ARIA-MeDALL hypothesis

Author

Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickmann, M, Bonini, M, Braido, F, Buhl, R, Bumbacea, R, Bush, A, Calderon, M, Calvo, G, Camargos, P, Caraballo, L, Cardona, V, Aguilar, D, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Akdis, M, Christoff, G, Chu, D K, Cingi, C, Correia da Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Ansotegui, I J, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Barbara, C, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Bedbrook, A, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Bindslev Jensen, C, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, O, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Gruta, S, Bosnic-Anticevich, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Mäkelä, M J, Martinez-Infante, E, Matricardi, P, Miculinic, N, Boulet, L P, Migueres, N, Mihaltan, F, Mohamad, Y, Moniusko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R E, Brightling, C E, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Brussino, L, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, R, Roballo-Cordeiro, C, Roche, N, Burte, E, Rodriguez-Gonzales, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Sarquis-Serpa, F, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Bustamante, M, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Canonica, G W, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, van Ganse, E, Van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Cecchi, L, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Celedon, J C, Zuberbier, T, Anto, J M, Chaves-Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Arshad, H S, Asayag, E, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, M, Blain, H, UCIBIO - Applied Molecular Biosciences Unit, Comprehensive Health Research Centre (CHRC) - pólo NMS, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
SDG 3 - Good Health and Well-being
Abstract

Asthma, rhinitis and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease", coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitisation and multimorbidity, (iii) advances in mHealth for novel phenotype definition, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis". This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitisation patterns (mono- or pauci-sensitisation versus polysensitisation), (iii) severity of symptoms and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and auto-immune diseases. authorsversion epub_ahead_of_print

Published
2023

28. Serum microRNAs Catalog Asthma Patients by Phenotype

Author

Gil-Martínez, M, primary, Rodrigo-Muñoz, JM, additional, Sastre, B, additional, Cañas, JA, additional, García-Latorre, R, additional, Redondo, N, additional, de la Fuente, L, additional, Mínguez, P, additional, Mahíllo-Fernández, I, additional, Sastre, J, additional, Quirce, S, additional, Caballero, ML, additional, Olaguibel, JM, additional, and del Pozo, V, additional

Published
2022
Full Text
View/download PDF

29. Sputum Inflammatory Patterns are Associated with Distinct Clinical Characteristics in Subjects with Occupational Asthma Independently from the Causal Agent

Author

Migueres, N, primary, Vandenplas, O, additional, Walusiak-Skorupa, J, additional, Wiszniewska, M, additional, Munoz, X, additional, Romero-Mesones, C, additional, Suojalehto, H, additional, Lindström, I, additional, van Kampen, V, additional, Merget, R, additional, Mason, P, additional, Maestrelli, P, additional, Sastre, J, additional, Quirce, S, additional, Rifflart, C, additional, Godet, J, additional, and de Blay, F, additional

Published
2022
Full Text
View/download PDF

31. Work-related dysphonia in subjects with sensitizer-induced occupational asthma is associated with neutrophilic inflammation

Author

Migueres, N, primary, Vandenplas, O, additional, Walusiak-Skorupa, J, additional, Wiszniewska, M, additional, Munoz, X, additional, Suojalehto, H, additional, Lindstrom, I, additional, Van Kampen, V, additional, Merget, R, additional, Mason, P, additional, Maestrelli, P, additional, Sastre, J, additional, Quirce, S, additional, Rifflart, C, additional, Godet, J, additional, and De Blay, F, additional

Published
2022
Full Text
View/download PDF

32. Multi-ancestral meta-analysis yields novel genetic loci for asthma exacerbations

Author

Herrera Luis, E, primary, Ortega, V E, additional, Ampleford, E J, additional, Sio, Y Y, additional, Granell, R, additional, De Roos, E, additional, Terzikhan, N, additional, Elorduy Vergara, E, additional, Hernandez-Pacheco, N, additional, Perez-Garcia, J, additional, Martin-Gonzalez, E, additional, Lorenzo-Diaz, F, additional, Hashimoto, S, additional, Brinkman, P, additional, Jorgensen, A L, additional, Yan, Q, additional, Forno, E, additional, Vijverberg, S J, additional, Lethem, R, additional, Espuela-Ortiz, A, additional, Gorenjak, M, additional, Eng, C, additional, González-Pérez, R, additional, Hernández-Pérez, J M, additional, Poza-Guedes, P, additional, Sardón, O, additional, Corcuera, P, additional, Hawkins, G A, additional, Marsico, A, additional, Bahmer, T, additional, Rabe, K F, additional, Hansen, G, additional, Kopp, M V, additional, Rios, R, additional, Cruz, M J, additional, González-Barcala, F, additional, Olaguibel, J M, additional, Plaza, V, additional, Quirce, S, additional, Canino, G, additional, Cloutier, M, additional, Del Pozo, V, additional, Rodriguez-Santana, J R, additional, Korta-Murua, J, additional, Villar, J, additional, Potočnik, U, additional, Figueiredo, C, additional, Kabesch, M, additional, Mukhopadhyay, S, additional, Pirmohamed, M, additional, Hawcutt, D B, additional, Melén, E, additional, Palmer, C N, additional, Turner, S, additional, Maitland-Van Der Zee, A H, additional, Von Mutius, E, additional, Celedón, J C, additional, Brusselle, G, additional, Chew, F T, additional, Bleecker, E, additional, Meyers, D, additional, G Burchard, E, additional, and Pino-Yanes, M, additional

Published
2022
Full Text
View/download PDF

33. Evolution of asthmatic patients at 6 and 12 months after acute COVID-19 recovery

Author

Camperos Moreno, R A, primary, Freund, P K E, additional, Pavón Guede, J, additional, Fernández-Concha Llona, I, additional, De Agrela Mendes, I, additional, Pose, K, additional, Laorden Escudero, D, additional, Romero Ribate, D, additional, Carpio Segura, C J, additional, Losantos García, I, additional, Marical Aguilar, P, additional, Fernández Navarro, I, additional, Arnalich Montiel, M V, additional, Gómez Carrera, L, additional, Alegre Segura, C, additional, Borobia Pérez, A M, additional, Prados Sánchez, C, additional, Quirce, S, additional, Domínguez Ortega, J, additional, Arnalich Fernández, F, additional, and Álvarez-Sala Walther, R, additional

Published
2022
Full Text
View/download PDF

34. Alpha-1 antitrypsin deficiency associates with asthma exacerbations

Author

Martín González, E, primary, Hernández-Pérez, J M, additional, González-Carracedo, M, additional, Pérez-García, J, additional, González-Pérez, R, additional, Mederos-Luis, E, additional, Sánchez-Machín, I, additional, Poza-Guedes, P, additional, Jesús Cruz, M, additional, González-Barcala, F J, additional, Martínez-Rivera, C, additional, Mullol, J, additional, Muñoz, X, additional, Olaguibel, J M, additional, Plaza, V, additional, Quirce, S, additional, Valero, A, additional, Sastre, J, additional, Del Pozo, V, additional, Villar, J, additional, Pérez, J A, additional, and Pino-Yanes, M, additional

Published
2022
Full Text
View/download PDF

35. Evaluation of Incidence and Complications during COVID-19 Desease in Patients with Asthma

Author

Pavon Guede, J, primary, Freund, P K E, additional, Camperos Moreno, R A, additional, De Agrela Mendes, I, additional, Pose, K, additional, Fernández Concha Llona, I, additional, Laorden Escudero, D, additional, Carpio Segura, C J, additional, Domínguez Ortega, J, additional, Romero Ribate, D, additional, Losantos García, I, additional, Quirce, S, additional, and Álvarez-Sala Walther, R, additional

Published
2022
Full Text
View/download PDF

41. List of Contributors

Author

Ahmed, J., primary, Asghar, A., additional, Aslam Maan, A., additional, Bannikova, A., additional, Basu, S., additional, Chakraborty, P., additional, Glicerina, V., additional, Hernández, M.J., additional, Houška, M., additional, Kasapis, S., additional, Muthukumarappan, K., additional, Naji-Tabasi, S., additional, Nazir, A., additional, Pérez-Quirce, S., additional, Prakash, S., additional, Ptaszek, P., additional, Razavi, S.M.A., additional, Romani, S., additional, Ronda, F., additional, Różańska, S., additional, Sahin, S., additional, Salvador, A., additional, Sanz, T., additional, Shivhare, U.S., additional, Sumnu, G., additional, Swamy, G.J., additional, Tatar, B.C., additional, Tornberg, E., additional, Tucker, G., additional, Villanueva, M., additional, and Žitný, R., additional

Published
2017
Full Text
View/download PDF

44. Role of the different healthcare professionals in the management of asthma patients. The GEMA-FORUM IV task force

Author

Quirce, S, primary, Trigueros, JA, additional, Ausín, P, additional, Muñoz Cano, R, additional, Ramírez Hernández, M, additional, González-Barcala, FJ, additional, Gregorio Soto, J, additional, Padilla Galo, A, additional, Cisneros Serrano, C, additional, Domínguez-Ortega, J, additional, Pueyo Bastida, A, additional, Pascual Erquicia, S, additional, Dávila, I, additional, Martínez Moragón, E, additional, Plaza Zamora, FJ, additional, Sánchez Barbero, F, additional, and Plaza, V, additional

Published
2022
Full Text
View/download PDF

45. Safe administration of SARS-CoV-2 vaccine after desensitization to a biologic containing polysorbate 80 in a patient with polyethylene glycol-induced severe anaphylaxis and sensitization to polysorbate 80

Author

Nin-Valencia, A, primary, Fiandor, A, additional, Lluch, M, additional, Quirce, S, additional, Caballero, T, additional, Heredia Revuelto, R, additional, González-Muñoz, M, additional, Caballero, ML, additional, and Cabañas, R, additional

Published
2022
Full Text
View/download PDF

46. Smell improvement by anti-IgE and anti-IL 5 biologics in patients with CRSwNP and severe asthma. A real life study

Author

Barroso, B, primary, Valverde-Monge, M, additional, Alobid, I, additional, Olaguibel, JM, additional, Rial, MJ, additional, Quirce, S, additional, Arismendi, E, additional, Barranco, P, additional, Betancor, D, additional, Bobolea, I, additional, Cárdaba, B, additional, Cruz Carmona, MJ, additional, Curto, E, additional, Domínguez-Ortega, J, additional, González-Barcala, FJ, additional, Martínez-Rivera, C, additional, Mahíllo-Fernández, I, additional, Muñoz, X, additional, Picado, C, additional, Plaza, V, additional, Rodrigo Muñoz, JM, additional, Soto-Retes, L, additional, Valero, A, additional, del Pozo, V, additional, Mullol, J, additional, and Sastre, J, additional

Published
2022
Full Text
View/download PDF

49. A new framework for the documentation and interpretation of oral food challenges in population‐based and clinical research

Author

Grabenhenrich, L. B., Reich, A., Bellach, J., Trendelenburg, V., Sprikkelman, A. B., Roberts, G., Grimshaw, K. E. C., Sigurdardottir, S., Kowalski, M. L., Papadopoulos, N. G., Quirce, S., Dubakiene, R., Niggemann, B., Fernández‐Rivas, M., Ballmer‐Weber, B., van Ree, R., Schnadt, S., Mills, E. N. C., Keil, T., and Beyer, K.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results